NIKKEI 225
38,073.98 -128.42 (-0.34%) HANG SENG
18,537.81 +223.91 (+1.22%) CRUDE OIL
79.68 +0.42 (+0.53%) GOLD FUTURES
2,353.30 +13.00 (+0.56%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,435.06 +1,736.81 (+3.57%)
Viking Therapeutics, Inc. (0VQA.L)
| Previous close | 78.73 |
| Open | 79.53 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 78.87 - 81.67 |
| 52-week range | 8.79 - 99.29 |
| Volume | |
| Avg. volume | 10,491 |
| Market cap | 56.731M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
- PR Newswire
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
- PR Newswire
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabol
